FDA’s Mixed Response To Indiplon Is Pfizer/Neurocrine’s Rude Awakening
This article was originally published in The Pink Sheet Daily
Executive Summary
Neurocrine will meet with FDA within 10 days to discuss the “approvable” and “not approvable” letters for the insomnia product.
You may also be interested in...
Neurocrine’s Bad Dream Continues: Indiplon FDA Approval Requires Three More Studies
FDA “approvable” letter for the insomnia agent is particularly stinging because Neurocrine was set to announce a new commercialization agreement with a leading pharma company.
Neurocrine’s Bad Dream Continues: Indiplon FDA Approval Requires Three More Studies
FDA “approvable” letter for the insomnia agent is particularly stinging because Neurocrine was set to announce a new commercialization agreement with a leading pharma company.
Neurocrine Partners With Dainippon To Market Indiplon In Japan
Dainippon Sumitomo will market Neurocrine Biosciences' insomnia agent indiplon in Japan under an exclusive liensing agreement announced Nov. 1